VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II trial designed to study the toxicity and Maximum Tolerated Dose (MTD) of
bortezomib in combination with BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan) and
autologous hematopoietic stem cell transplantation (ASCT) and to obtain a preliminary
estimate of the response rate to this combination.